公开(公告)号：US20230263805A1

公开(公告)日：2023-08-24

申请号：US18141999

申请日：2023-05-01

申请人： GABA Therapeutics Inc.

发明人： Olivier Dasse

IPC分类号： A61K31/535 ,  A61P25/00 ,  A61K31/536 ,  A61K31/015 ,  A61K31/03 ,  C07B59/00 ,  C07D265/18

CPC分类号： A61K31/535 ,  A61P25/00 ,  A61K31/536 ,  A61K31/015 ,  A61K31/03 ,  C07B59/002 ,  C07D265/18 ,  A61K2300/00

摘要： This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.

公开(公告)号：US11672805B2

公开(公告)日：2023-06-13

申请号：US16988586

申请日：2020-08-07

申请人： GABA Therapeutics Inc.

发明人： Olivier Dasse

IPC分类号： A61K31/535 ,  A61P25/00 ,  A61K31/536 ,  A61K31/015 ,  A61K31/03 ,  C07B59/00 ,  C07D265/18

CPC分类号： A61K31/535 ,  A61K31/015 ,  A61K31/03 ,  A61K31/536 ,  A61P25/00 ,  C07B59/002 ,  C07D265/18 ,  A61K2300/00

摘要： This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.

公开(公告)号：US20240189316A1

公开(公告)日：2024-06-13

申请号：US18493488

申请日：2023-10-24

申请人： Gaba Therapeutics Inc.

发明人： Olivier Dasse ,  Mario Saltarelli

IPC分类号： A61K31/536 ,  A61K9/00 ,  A61P25/22

CPC分类号： A61K31/536 ,  A61K9/0053 ,  A61P25/22

摘要： The present invention relates to deuterated etifoxine compositions and methods for administration without autoinduction of metabolism in the treatment of a variety of diseases. disorders, or conditions.